Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study

Da Hyun Kang; Soon Hyo Kwon; Bark Lynn Lew

doi:10.1111/1346-8138.17017

Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study

Da Hyun Kang, Soon Hyo Kwon, Bark Lynn Lew

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	e63-e65
Journal	Journal of Dermatology
Volume	51
Issue number	3
DOIs	https://doi.org/10.1111/1346-8138.17017
Publication status	Published - Mar 2024

Access to Document

10.1111/1346-8138.17017

Cite this

@article{f35138610cc34f938ca3e8c98d2e0535,

title = "Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study",

author = "Kang, {Da Hyun} and Kwon, {Soon Hyo} and Lew, {Bark Lynn}",

year = "2024",

month = mar,

doi = "10.1111/1346-8138.17017",

language = "English",

volume = "51",

pages = "e63--e65",

journal = "Journal of Dermatology",

issn = "0385-2407",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis

T2 - A real-world retrospective study

AU - Kang, Da Hyun

AU - Kwon, Soon Hyo

AU - Lew, Bark Lynn

PY - 2024/3

Y1 - 2024/3

UR - http://www.scopus.com/inward/record.url?scp=85176459595&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.17017

DO - 10.1111/1346-8138.17017

M3 - Letter

C2 - 37950501

AN - SCOPUS:85176459595

SN - 0385-2407

VL - 51

SP - e63-e65

JO - Journal of Dermatology

JF - Journal of Dermatology

IS - 3

ER -

Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study

Access to Document

Other files and links

Dupilumab for Eczema: Spotlighting 4-Year Survival Rate Data; This long-term data on dupilumab investigated both survival rates and rationale for treatment discontinuation.

Dupilumab for Eczema: Spotlighting 4-Year Survival Rate Data

Cite this

Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study

Access to Document

Other files and links

Press/Media

Dupilumab for Eczema: Spotlighting 4-Year Survival Rate Data; This long-term data on dupilumab investigated both survival rates and rationale for treatment discontinuation.

Dupilumab for Eczema: Spotlighting 4-Year Survival Rate Data

Cite this